Search clinical trials for: SOM230 LAR 30 mg

Total 493 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Cushing's Disease

Italy, Belgium, Japan, Germany, United Kingdom, Thailand, Spain, France, Netherlands, Turkey, Israel, China, United States, Canada, India, Argentina, Brazil, Peru, Poland, Russian Federation
Lynn Feun

Completed

Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Ambrilia Biopharma, Inc.

Completed

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

Belarus, Hungary, Romania, Serbia, Slovakia, Ukraine
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Acromegaly | Pituitary Gigantism

Japan
Azidus Brasil

Suspended

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

Acromegaly

Brazil
Cedars-Sinai Medical Center
Novartis Pharmaceuticals

Completed

Ultrasound Guided Octreotide LAR Injection in Acromegaly

Acromegaly

United States
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)

Completed

Effects of Electronic Cigarette Settings and Liquid Concentrations in Cigarette Smokers and Electronic Cigarette Users

Electronic Cigarettes

United States
Novartis Pharmaceuticals

Completed

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial (LUNA)

Neuroendocrine Carcinoma of the Lung and Thymus

Italy, United Kingdom, Netherlands, Spain, Germany, France, Greece, Denmark, Sweden
Novartis

Terminated

Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.

Proliferative Diabetic Retinopathy

Switzerland
Erasmus Medical Center
Novartis

Unknown

Pasireotide LAR and Pegvisomant Study in Acromegaly (PAPE)

Acromegaly

Netherlands
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)

Terminated

Effects of E-Cigarette Power and Nicotine Content in Dual Users and Vapers

Electronic Cigarettes

United States
Novartis Pharmaceuticals

Completed

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Neuroendocrine Tumors

United States
University of Pennsylvania

Terminated

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas (LAR)

Gonadotroph Adenomas

United States
Novartis Pharmaceuticals

Completed

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Acromegaly

Italy
Novartis Pharmaceuticals

Terminated

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Pituitary Neoplasm | Pancreatic Neoplasm | Ectopic ACTH Syndrome | Nelson Syndrome

Germany, Italy, Australia, Russian Federation, Spain, Thailand, France, Canada, Brazil, United States, Argentina, Mexico
Donesta Bioscience

Completed

Effect of Food on the Bioavailability of 30 mg Estetrol (E4) Tablet in Healthy Postmenopausal Female Volunteers

Food-effect

Bulgaria
Novartis Pharmaceuticals

Completed

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Acromegaly

Italy, Belgium, United Kingdom, Bulgaria, Turkey, France, Portugal, China, Argentina, Brazil, Colombia, Hungary, Malaysia, Mexico, Romania
Novartis Pharmaceuticals

Terminated

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET (COOPERATE-2)

Islet Cell Tumor

France, Spain, United Kingdom, Belgium, Hungary, Turkey, Canada, Argentina, Sweden, Italy, Thailand, Germany, Netherlands, Brazil, Australia, Japan, United States, Denmark, New Zealand
Fondazione Oncotech

Not yet recruiting

NEOadjuvant Abemaciclib and GIredestrant triaL in Patients With ER-positive, HER2-negative Early Breast Cancer (Neo-AGILE)

Breast Cancer

Italy
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Respiratory Syncytial Virus Infections

United States, Australia, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Hungary, Netherlands, New Zealand, Panama, Puerto Rico, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
Galderma R&D

Completed

An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis

Prurigo Nodularis

United States, Germany, Austria, Canada, Denmark, Hungary, Italy, Poland, Sweden, United Kingdom
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Hepatic Impairment | Healthy Participants

United States
Otsuka Pharmaceutical Development & Commercialization...
Bill and Melinda Gates Foundation

Completed

A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis

Pulmonary TB

South Africa
Allergan

Completed

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Chronic Migraine

United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Sweden, Taiwan, United Kingdom
Novartis Pharmaceuticals

Approved for marketing

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (ACCESS)

Acromegaly

United States
Vigonvita Life Sciences

Completed

Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Healthy Subjects

China
GlaxoSmithKline

Completed

A New Oral Treatment For Type II Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Germany, Canada, Sweden, Latvia, Finland, Greece, Romania, Czechia, Puerto Rico
Merck Sharp & Dohme LLC

Terminated

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Anemia | Bladder Cancer | Cancer of Head and Neck | Uterine Cervical Cancer | Carcinoma, Small-Cell Lung
MedImmune LLC

Completed

A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults

Asthma

United States, Canada, Peru, Taiwan, Colombia, Brazil, Panama, Philippines, Argentina, Costa Rica
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants

Healthy

Belgium
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary, Puerto Rico
Patrick Y. Wen, MD
Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital; Northwestern... and other collaborators

Completed

Monthly SOM230C for Recurrent or Progressive Meningioma

Meningioma

United States
Pfizer

Completed

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)

Healthy

Sweden
Prof. Dr. Berthold Schalke
Crolll Gmbh

Completed

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

Primary Inoperable Thymoma | Local Recurrent Thymoma

Germany
Cerevel Therapeutics, LLC

Recruiting

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary
NEURALIS s.a.

Recruiting

Single and Multiple Intravenous Administrations of Estetrol (E4) in Healthy Adult Volunteers

Pharmacokinetics | Safety

Bulgaria
Cerevel Therapeutics, LLC

Recruiting

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

Healthy Volunteer

Japan
Shire

Completed

A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®

Hunter Syndrome

United States, United Kingdom
Pfizer

Terminated

A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

Healthy

Singapore
Beijing Continent Pharmaceutical Co, Ltd.

Completed

Study on Hydronidone Capsule BE

Healthy

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Pfizer

Completed

A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects

Healthy Volunteers

Belgium
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Symptomatic Refractory Resistant Carcinoid Disease

United Kingdom, Belgium, Italy, Singapore, Austria, France, Israel, Sweden, Germany, Spain, Canada, Argentina, Poland, United States, Brazil, Norway
Virginia Commonwealth University

Completed

Assessing Electronic Cigarette Nicotine Flux

Electronic Cigarette Use

United States
GlaxoSmithKline

Completed

First Time in Human Study Using GSK2330672

Diabetes Mellitus, Type 2

United States
Johnson & Johnson Pharmaceutical Research & Development...

Withdrawn

Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma

Asthma
ViiV Healthcare

Completed

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Infection, Human Immunodeficiency Virus

United States
MedImmune LLC

Completed

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

Healthy Volunteer

United Kingdom

Search clinical trials for: SOM230 LAR 30 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations